Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Accumulation of DNA Damage and Alteration of the DNA Damage Response in Chronic Myeloid Leukemia

Henning D. Popp, Vanessa Kohl, MSc, Johanna Flach, PhD, Susanne Brendel, MTA, Helga Kleiner, MTA, Wolfgang Seifarth, PhD, Christel Weiss, PhD, Susanne Saussele, MD, Wolf-Karsten Hofmann, MD PhD, Alice Fabarius, PhD

Blood (2019) 134 (Supplement_1): 5364.

https://doi.org/10.1182/blood-2019-122698

Published: 2019

Journal Articles

Anti-Leukemic Efficacy of Talazoparib and APE1 Inhibitor III Combined with Decitabine in Myeloid Malignancies

Vanessa Kohl, MSc, Susanne Brendel, MTA, Johanna Flach, PhD, Helga Kleiner, MTA, Christel Weiss, PhD, Wolfgang Seifarth, PhD, Daniel Nowak, MD, Wolf-Karsten Hofmann, MD PhD, Alice Fabarius, PhD, Henning D. Popp

Blood (2019) 134 (Supplement_1): 5056.

https://doi.org/10.1182/blood-2019-122672

Published: 2019

Journal Articles

Increase of DNA Damage and Alteration of the DNA Damage Response in Monoclonal B-Cell Lymphocytosis and Chronic Lymphocytic Leukemia

Henning D. Popp, MD, Susanne Brendel, MTA, Sabrina Ruppenthal, PhD, Helga Kleiner, MTA, Sven Schneider, MD, Torsten Schulze, MD, Christel Weiss, PhD, Frederik Wenz, MD, Wolf-Karsten Hofmann, MD, Alice Fabarius

Blood (2017) 130 (Supplement 1): 4300.

https://doi.org/10.1182/blood.V130.Suppl_1.4300.4300

Published: 2017

Journal Articles

Safety and Efficacy of the CD95-Ligand Inhibitor APG101 in Transfusion-Dependent Patients with Low Risk MDS: Results from a Phase I Study

Tobias Boch, MD, Thomas Luft, MD PhD, Maximilian Mossner, Johann-Christoph Jann, Daniel Nowak, MD, Christine Folz, Jennifer Klemmer, Susanne Brendel, Harald Fricke, MD, Claudia Kunz, PhD, Wolf-Karsten Hofmann, MD, Florian Nolte, MD

Blood (2016) 128 (22): 228.

https://doi.org/10.1182/blood.V128.22.228.228

Published: 2016

Journal Articles

γH2AX Foci Increase Across the Spectrum from Myelodysplastic Syndromes to Acute Myeloid Leukemias and Co-Localize with 53BP1 in Specific Patterns in the Context of an Impaired DNA Damage Response

Henning D Popp, MD, Susanne Brendel, Nicole Naumann, Thomas Henzler, MD, Wolf-Karsten Hofmann, MD, Alice Fabarius, PhD

Blood (2016) 128 (22): 5226.

https://doi.org/10.1182/blood.V128.22.5226.5226

Published: 2016

Journal Articles

The Fas Ligand Inhibitor APG101 in Transfusion Dependent Patients with Low Risk MDS: Interim Results from a Phase I Study

Evi launiger-Lörsch, Thomas Luft, Stephanie Fey, Julia Obländer, Susanne Brendel, Jovita Pressler, Johann-Christoph Jann, Claudia Kunz, Anthony D. Ho, Harald Fricke, Maximilian Mossner, Georgia Metzgeroth, Daniel Nowak, Wolf-Karsten Hofmann, Florian Nolte

Blood (2014) 124 (21): 4669.

https://doi.org/10.1182/blood.V124.21.4669.4669

Published: 2014

Journal Articles

The New CD95 Ligand Inhibitor APG101 Leads To Decreased Apoptosis and Improved Erythroid Differentiation In Primary CD34+ Cells From Patients With Low Risk Myelodysplastic Syndrome (MDS)

Florian Nolte, MD, Claudia Kunz, Stephanie Fey, Julia Obländer, Susanne Brendel, Marion Klaumünzer, Maximilian Mossner, Johann-Christoph Jann, Stefanie Uhlig, Daniel Nowak, MD, Harald Fricke, MD, Wolf-Karsten Hofmann, MD

Blood (2013) 122 (21): 1562.

https://doi.org/10.1182/blood.V122.21.1562.1562

Published: 2013

Journal Articles

Detection of Highly Clonal CD34 + , Mononuclear Bone Marrow and Peripheral Blood Cells From Patients with Myelodysplastic Syndrome and Age Related Increase of Clonal Hematopoiesis In Healthy Subjects Using a Novel Transcriptional Pyrosequencing Based Clonality Assay

Maximilian Mossner, Daniel Nowak, MD, Marion Klaumünzer, Verena Nowak, Katrin Ackermann, Susanne Brendel, Julia Obländer, Olaf Hopfer, Claudia Baldus, Eckhard Thiel, Wolf-Karsten Hofmann

Blood (2010) 116 (21): 977.

https://doi.org/10.1182/blood.V116.21.977.977

Published: 2010

NARROW

Accumulation of DNA Damage and Alteration of the DNA Damage Response in Chronic Myeloid Leukemia

Anti-Leukemic Efficacy of Talazoparib and APE1 Inhibitor III Combined with Decitabine in Myeloid Malignancies

Increase of DNA Damage and Alteration of the DNA Damage Response in Monoclonal B-Cell Lymphocytosis and Chronic Lymphocytic Leukemia

Safety and Efficacy of the CD95-Ligand Inhibitor APG101 in Transfusion-Dependent Patients with Low Risk MDS: Results from a Phase I Study

γH2AX Foci Increase Across the Spectrum from Myelodysplastic Syndromes to Acute Myeloid Leukemias and Co-Localize with 53BP1 in Specific Patterns in the Context of an Impaired DNA Damage Response

The Fas Ligand Inhibitor APG101 in Transfusion Dependent Patients with Low Risk MDS: Interim Results from a Phase I Study

The New CD95 Ligand Inhibitor APG101 Leads To Decreased Apoptosis and Improved Erythroid Differentiation In Primary CD34+ Cells From Patients With Low Risk Myelodysplastic Syndrome (MDS)

Detection of Highly Clonal CD34 + , Mononuclear Bone Marrow and Peripheral Blood Cells From Patients with Myelodysplastic Syndrome and Age Related Increase of Clonal Hematopoiesis In Healthy Subjects Using a Novel Transcriptional Pyrosequencing Based Clonality Assay

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only